Incyte | INCY - Sales Revenues


Incyte reported $1.56B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agenus USD 33.7M 500K Mar/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.1B 1.48B Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Exelixis USD 658.69M 30M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 100M 289M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.52B 112M Sep/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026